Abstract
Non-Hodgkin lymphoma is the third most common malignancy in children. The cure rate in developed countries for most of the subtypes exceeds 75 % with some subtypes doing even better. These cure rates have been attained using aggressive protocols that need adequate resources and support. Some of these protocols are not suitable for LMIC but there are many other suitable protocols available in the literature for use in these countries. They vary from oral-based protocols to more intensive but easily manageable protocols.
Keywords
- Primary Central Nervous System Lymphoma
- Burkitt Lymphoma
- Anaplastic Large Cell Lymphoma
- Mediastinal Mass
- Tumour Lysis Syndrome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Childhood non-Hodgkin lymphoma treatment. www.cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/Healthprofessional/ Accessed 07/2012
Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011 (Chapter 23: Malignant non-Hodgkin lymphomas in children).
Alexander D, Mink P, Adami H, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer. 2007;120:1–39.
Lanzkowsky P. Manual of pediatric hematology and oncology. 3rd ed. San Diego: Academic; 2000. (Chapter 13).
Wakabi W. Special report: Kenya and Uganda grapple with Burkitt lymphoma. Lancet Oncol. 2008;9(4):319.
Ahmad N, Zaidi A, Badar F, et al. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin’s lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol. 2010;6:49–56.
Moleti M, Al-Hadad S, Al-Jadiry M, et al. Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer. 2011;56:560–7.
Baez F, Pillon M, Manfredini L, et al. Treatment of pediatric non-hodgkin lymphomas in a country with limited resources: Results of the First National Protocol in Nicaragua. Pediatr Blood Cancer. 2011;56:560–7.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med. 1996;334(19):1238–48.
Leoncini L, Raphael M, Stein H. BL. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer: Lyon; 2008. p. 262–4.
Percy CL, Smith MA, Linet M, et al. Lymphomas and reticuloendothelial neoplasms. In: Ries LA, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999. NIH Pub. No. 99-4649, p. 35–50. Also available online. Last accessed Oct 5, 2012.
Wright D, McKeever P, Carter R. Childhood non Hodgkin lymphomas in the United Kingdom; findings from the UK Children’s Cancer Study Group. J Clin pathol. 1997;50:128–34.
Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107(10):4047–52.
Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35(1):20–7.
Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504.
Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516–26.
Samuelsson BO, Ridell B, Röckert L, et al. Non-Hodgkin lymphoma in children: a 20-year population-based epidemiologic study in western Sweden. J Pediatr Hematol Oncol. 1999;21:103–10.
Murphy SB, Fairclough DL, Hutchison RE, et al. Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7(2):186–93.
Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol. 1991;9(4):539–47.
Magrath IT. African Burkitt’s lymphoma. history, biology, clinical features and treatment. Am J Pediatr Hematol Oncol. 1991;13(2):222–46.
Aderele WL, Antia AU. Burkitt’s lymphoma in Ibadan: a review of 133 cases. Nig J Paediatr. 1979;6:1–14.
Mbulaiteye SM, Anderson WF, Bhatia K, et al. Trimodal age-specific incidence patterns for BL in the United States, 1973–2005. Int J Cancer. 2010;126(7):1732–9.
Mbulaiteye SM, Biggar RJ, Bhatia K, et al. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer. 2009;53(3):366–70. doi:10.1002/pbc.22047.
Orem J, Maganda A, Mbidde EK, et al. Clinical characteristics and outcome of children with BL in Uganda according to HIV infection. Pediatr Blood Cancer. 2009;52(4):455–8. doi:10.1002/pbc.21769.).
Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol. 2008;142(3):329–47.
Cairo MS, Gerrard M, Patte C. A new protocol for treatment of mature B-cell lymphoma/leukaemia (BCLL): FAB LMB 96, a SFOP LMB 96/CCG-5961/UKCCSG NHL 9600 international cooperative study. Med Pediatr Oncol. 1997;29:320a.
Magrath IT, Lwanga S, Carswell W, et al. Surgical reduction of tumour bulk in the management of abdominal Burkitt’s lymphoma. Br Med J. 1974;2:308–12.
Ngoma T, Adde M, Durosinmi M, et al. Treatment of BL in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Br J Haematol. 2012;158(6):749–62.
Ensani F, Mehravaran S, et al. Fine-needle aspiration cytology and flow cytometric immunophenotyping in diagnosis and classification of non-Hodgkin lymphoma in comparison to histopathology. Diagn Cytopathol. 2012;40(4):305–10. doi:10.1002/dc.21561.
Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy irradiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. J Clinc Oncol. 1986;4:716–21.
Boreintein SH, Gerstle T, Malkin D, et al. The effect of prebiopsy corticosteroid treatment on the diagnosis of mediastinal lymphoma. J Pediatr Surg. 2000;35:973–6.
Nathan and Oski’s Hematology of Infancy and Childhood. Nathan DG, Ginsburg D, Orkin SH, Look AT (editors). 6th Edition. Saunders, Philadelphia 2003 (Chapter 33).
Hesseling P, Molyneux E, Kamiza S, et al. Endemic Burkitt Lymphoma: a 28 day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Med. 2009;29:29–34.
Bezwoda W, Rastogi R, Valla A, et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimes in patients with intermediate and high grade non-Hodgkin’s lymphoma. Eur J Cancer. 1995;31A(6):903–11.
Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: Is it possible to reduce treatment for the early responding patients? Blood. 2007;109(7):2773–80.
Hesseling P, Njume E, Kouya F, et al. The Cameroon 2008 Burkitt Lymphoma Protocol: improved event free survival with treatment adapted to disease stage and response to induction therapy. Pediatr Hematol Oncol. 2012;29:119–29.
Traore F, Coze C, Atteby J, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Paediatric oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56:70–6.
Atra A, Meller S, Steven R, et al. Conservative management of follicular non-Hodgkin lymphoma in children. Br J Haematol. 1998;103:220–3.
Lorsbach R, Shay-Seymore D, Moore J, et al. Clinicopathological analysis of follicular lymphoma occurring in children. Blood. 2002;99(6):1959–64.
Hutchinson R, Laver J, Chang M, et al. Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: a children’s oncology group study. Pediatr Blood Cancer. 2008;51:29–33.
Landman E, Oschlies I, Zimmermann M, et al. Secondary non-Hodgkin lymphoma (NHL) in children and adolescents after cancer other than NHL. Br J Haem. 2008;143:387–94.
Hesseling P, Israels T, Harif M, et al. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) I a resource limited setting. Pediatr Blood Cancer. 2013;60:357–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Stones, D.K., Brown, B.J. (2014). Non-Hodgkin Lymphoma. In: Stefan, D., Rodriguez-Galindo, C. (eds) Pediatric Hematology-Oncology in Countries with Limited Resources. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3891-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3891-5_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3890-8
Online ISBN: 978-1-4614-3891-5
eBook Packages: MedicineMedicine (R0)